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OBJECTIVES The objective of this study was to examine whether the delta (d) opioid receptor isoform is
expressed in the human heart and whether this receptor improves contractile function after
hypoxic/reoxygenation injury.
BACKGROUND Delta opioid receptor agonists mimic preconditioning (PC) in rat myocardium, correspond-
ing to known cardiac d opioid receptor expression in this species.
METHODS The messenger RNA transcript encoding the d opioid receptor was identified in human atria
and ventricles. To evaluate the cardioprotective role of the opioid receptor, human atrial
trabeculae from patients undergoing coronary bypass grafting were isolated and superfused
with Tyrode’s solution. A control group underwent 90 min of simulated ischemia and
120 min of reoxygenation. A second group was preconditioned with 3 min simulated ischemia
and 7 min reoxygenation. Additional groups included: superfusion with the d receptor agonist
(DADLE) (10 nM), with the d receptor antagonist naltrindole (10 nM) and with the
mitochondrial KATP channel blocker 5-hydroxydecanoate (5HD) (100 mM) either with or
without PC, respectively. A final group was superfused with 5HD before DADLE. The end
point used was percentage of developed force after 120 min of reoxygenation.
RESULTS Results, expressed as means 6 SEM, were: control 5 32.6 6 3.8%; PC 5 50.5% 6 1.8*;
DADLE 5 46.0 6 3.9%*; PC 1 naltrindole 5 25.5 6 3.9%; naltrindole alone 5 25.5 6
4.3%; 5HD 1 PC 5 28.9 6 7.4%; 5HD alone 5 24.1 6 3.0%; 5HD 1 DADLE 5 26.9 6
4.4% (*p , 0.001 vs. controls).
CONCLUSIONS Human myocardium expresses the d opioid receptor transcript. Stimulation of this receptor
appears to protects human muscle from simulated ischemia, similar to PC, and via opening
of the mitochondrial KATP channel. (J Am Coll Cardiol 2000;36:2296–302) © 2000 by the
American College of Cardiology
Ischemic preconditioning (PC) is the phenomenon, widely
demonstrated in many species, whereby the myocardium is
protected from a major ischemic insult by a prior, brief
period of ischemia or hypoxia followed by reperfusion or
reoxygenation. First demonstrated in 1986 by Murry et al.
(1), the mechanisms underlying PC are still not fully
clarified but are believed to involve release of adenosine
(2,3), bradykinin (4), noradrenaline (5) and endothelin (6),
which then trigger intracellular enzyme cascades and may
ultimately lead to the opening of the mitochondrial KATP
channel (7–9). More recently the role of opioids in cardio-
protection by PC has been examined. In the rat model of
myocardial infarction, pharmacological PC by morphine
reduces infarct size similarly to ischemic PC (10) through a
mechanism that is inhibited by the sulphonylurea, gliben-
clamide. This effect suggests an involvement of the ATP
sensitive potassium channel (KATP) (10,11). Importantly,
glibenclamide can also abolish the effects of PC during
angioplasty in humans (12), suggesting a role for this
channel in classic PC. More recently, emphasis has shifted
from the sarcolemmal to the mitochondrial KATP channel
that is inhibited by 5-hydroxydecanoate (5HD) (8,9).
The three main opioid receptor subtypes are m, k and d.
Differential tissue specific opioid receptor subtype expres-
sion has been described in rats (13). Furthermore, in rat
myocardium Gross and colleagues (14) have shown that
stimulation of the d1 opioid receptor subtype mediates
cardioprotection similar to PC. However, the distribution of
the subtypes in the human myocardium is not known. In
this study our aims were, first to delineate by using semi-
quantitative reverse transcriptase-polymerase chain reaction
(PCR), the relative expression levels of genes encoding the
opioid receptor isoforms in human atria and ventricular
tissue. Our second aim was to establish the role of d opioid
receptors in cardiac protection in an isolated human muscle
preparation, using a d receptor agonist (DADLE) (D-Ala2-
Leu-enkephalin), and naltrindole, a d receptor antagonist.
Our third aim was to ascertain the potential role of the
mitochondrial KATP channel in any protection achieved by
d opioid stimulation. Furthermore, we have recently dem-
onstrated that cardiac kappa receptors appear to mediate an
anti-PC signaling in the rat heart (15). Thus, it is important
to know whether these receptors exist in the human heart. If
so, kappa-mediated inhibitory signals could lessen or abro-
gate any potential beneficial effects of opioid receptor
agonists that exhibit a wide range of receptor subtype
activity, such as morphine.
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METHODS
RNA isolation and RT-PCR analysis of human atria and
ventricular tissue. Right atrial appendage biopsies were
taken from patients undergoing elective coronary bypass
grafting or aortic valve replacement. Ventricular tissue was
used from patients who were undergoing mitral valve
replacement. Tissue was excluded from patients with heart
failure, arrhythmias or on antiarrhythmic or oral hypogly-
cemic therapy. RNA extraction and quantification were
performed as described previously (16). Using the Gene-
Amp EZrTth RNA PCR Kit (Perkin Elmer; New Jersey)
we determined the presence of m, k and d opioid receptors.
Specific PCR primers for the human m, k and d opioid
receptors were designed using the published receptor se-
quences (Genebank Accession No’s: NM000914, U11053
and U07882, respectively). These reactions produced PCR
products of expected sizes 1,347 base pair, 417 bp and
370 bp, respectively. Restriction digestions were performed
using HIND III (Promega, Madison, Wisconsin) to con-
firm the m receptor PCR product. The d and k PCR
products conformed to the expected size on gel electro-
phoresis. Polymerase chain reaction products were com-
pared using densitometric analysis using 0.5, 1.0 and 2.0 mg
of total RNA with each set of primers using different cycle
numbers (30, 35 and 40 cycles). Control primers encoding
glyceraldehyde-phosphate dehydrogenase were used con-
comitantly under the same conditions. The k transcript was
not visualized after the 40 cycles of PCR. To evaluate
whether this transcript was present in very low copy number
in the human atria and ventricles, nested PCR with addition
primers was performed.
Human atrial trabeculae model. Atrial trabeculae were
taken from patients with chronic stable angina undergoing
elective coronary bypass grafting or aortic valve replacement.
Exclusion criteria were the same as described for RNA
isolation. Prior ethical approval had been granted by the
Ethics and Clinical Investigation Panel of the Middlesex
Hospital. The method of harvesting atrial trabeculae tissue,
placing it in an organ bath and mechanical recording of
stimulated contractions were as previously published
(17,18). In brief, trabeculae were placed in the organ bath
and allowed to equilibrate for 45 to 60 min. All the groups
underwent a period of 90 min of simulated ischemia
followed by 120 min reoxygenation. The ischemic PC
protocol consisted of 3 min of hypoxic, substrate-free
superfusion with rapid pacing (3 Hz) followed by 7 min of
reoxygenation. A third group were superfused with
DADLE (10 nMol), for 5 min followed by a 7 min washout
period before the 90 min period of simulated ischemia and
reoxygenation (n 5 9). The d receptor antagonist, naltrin-
dole (10 nMol), was superfused for 10 min before and then
during simulated ischemic PC (n 5 7). The same dose of
naltrindole was also superfused alone for 20 min before
simulated ischemia and reoxygenation (n 5 6). The mito-
chondrial KATP channel blocker, 5-hydroxydecanoate
(5HD) (100 mM), was superfused before PC with simulated
ischemia (n 5 6) before superfusion with DADLE (n 5 6)
and alone (n 5 5). Figure 1 outlines the experimental
protocols followed. Developed force was measured through-
out the experiment. The end point was taken as developed
force as a percentage of baseline developed force after 2 h of
reperfusion.
Statistical analysis. All results are expressed as group
means 6 standard error of the mean. Differences between
groups were evaluated by analysis of variance. Fisher pro-
tected least significant difference post hoc test was used for
multiple comparisons between the groups. A p value , 0.01
was considered significant.
RESULTS
RT-PCR amplification of m, k and d opioid receptor
messenger RNA. Gel electrophoresis of PCR products
from human right atrial RNA were analyzed on a 2%
agarose gel stained with ethidium bromide. The results are
shown in Figure 2. The band consistent with that expected
for the d and m opioid receptor were reproducibly obtained.
We concluded that the d and m opioid receptors are present
in human atrial tissue. We were unable to detect any k
opioid receptor using the primary round of PCR. When
using nested primers, however, a faint band of appropriate
size was found. These data suggest that the k receptors are
present in the human atria but at a much lower copy number
than for d and m receptors. However, due to the low
abundance of this k receptor isoform, we cannot exclude
that the PCR product amplified comes from neuronal tissue
within the myocardium as opposed to true myocardial
expression of this receptor. We repeated our investigation
for m, k and d opioid receptors in human right ventricular
tissue obtained during mitral valve replacement. Our results
show the presence in human ventricular tissue of m and d
receptors at a similar copy number to human atrial tissue,
with evidence of a lower copy number of the k receptors
when using the second round of nested PCR (Fig. 2).
Human atrial trabeculae model. Fifty-two samples were
obtained from 27 patients with stable ischemic heart disease
(20 men and 7 women; age range 42 to 80 years, mean age
62.7 years). No trabeculae were excluded in this study. If
two suitable trabeculae could be dissected from one atrial
appendage, then each trabeculae was allocated to one of the
eight groups (two sets of apparatus were used simulta-
Abbreviations and Acronymns
DADLE 5 delta opioid agonist
naltrindole 1 PC 5 naltrindole plus preconditioning
PC 5 preconditioning
PCR 5 polymerase chain reaction
5HD 5 5-hydroxydecanoate
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neously) as per previous studies (17,18). After an initial
period of stabilization, samples, apart from those acting as
controls, were pretreated before undergoing a period of
simulated ischemia, which involved superfusion with a
hypoxic, substrate free modified Tyrode’s solution and
pacing at 3 Hz. This was followed by reperfusion with an
oxygenated solution for 120 min (Fig. 1). Baseline resting
force was manipulated to the same value in all samples, and
there was no significant difference in developed force at the
end of the stabilization period between groups (Table 1).
Experimental data are presented graphically as a percentage
of baseline developed force with developed force at the end
of the stabilization period taken as 100% developed force.
Figure 3 demonstrates the role of the d opioid receptor.
Preconditioning alone and with concomitant naltrindole
caused an initial fall in the developed force of the trabeculae
to 16.4 6 3.0% and 30.9 6 6.4%, respectively. In both
groups values returned to baseline before the onset of
simulated ischemia. Superfusion with DADLE or naltrin-
dole gave values for developed force of 109 6 4.9% and
93.1 6 5.6% (both NS vs. controls) of values at the onset of
simulated ischemia. During the hypoxic period, there were
no significant differences between the functions of all groups
studied. After the 120 min superfusion with reoxygenated
modified Tyrode’s solution, there was greater recovery of
function in the groups preconditioned by simulated isch-
emia and DADLE (control, 32.6 6 3.8%; PC, 50.5 6
1.8%; DADLE, 46 6 3.9%; p , 0.001 vs. controls; no
significant difference between PC and DADLE groups).
The recovery values for the control group, the group
superfused with naltrindole alone and the group combining
naltrindole with PC did not differ from each other (naltrin-
dole, 25.3 6 4.3%; naltrindole 1 PC, 25.5 6 3.9%).
Figure 4 compares the involvement of the KATP channel
in both simulated ischemic and opioid PC. The trabeculae
that were preconditioned with simulated ischemia and were
preconditioned with 5HD 1 PC both decreased function
before the onset of 90 min simulated ischemia (PC, 16.4 6
3.0%; 5HD 1 PC, 24.9 6 5.6%) compared with the other
groups. After 120 min reoxygenation modified Tyrode’s
solution, the trabeculae preconditioned with simulated isch-
emia and the d opioid agonist, DADLE, recovered to
50.5 6 1.8% and 46 6 3.9%, respectively (p , 0.001).
When trabeculae preconditioned with simulated ischemia
Figure 1. Experimental protocols for eight experimental groups. All protocols were preceded by a stabilization period of 45 to 60 min. This was followed
by 90 min of simulated ischemia (superfusion with hypoxic, substrate free Modified Tyrodes solution and pacing at 3 Hz) and 120 min of superfusion with
reoxygenated Tyrodes solution. Control 5 C; preconditioning 5 PC; delta opioid agonist 5 DADLE; naltrindole 1 preconditioning 5 naltrindole 1 PC;
5-hydroxydecanoate 5 5HD. Solid box 5 simulated ischemia; open box 5 normoxic superfusion.
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and DADLE were also superfused with 5HD, the protec-
tion from preconditioning was lost (5HD 1 PC, 28.9 6
7.4%; 5HD 1 DADLE, 26.9 6 4.8%). Trabeculae super-
fused with 5HD initially without additional precondition-
ing recovered to 24.1 6 3.9% of their baseline value. For
these three groups the functional recovery attained did not
differ from controls (32.6 6 3.8%).
DISCUSSION
That activation of opioid receptors may confer a degree of
cardioprotection in humans is a potentially important con-
cept. This study is the first to show that stimulation of the
opioid d receptor in superfused human atria can achieve
protection similar to that obtained by PC induced by
simulated ischemia, as evidenced by improved reoxygen-
ation mechanical function. We found that short periods of
exposure to the d opioid receptor agonist, DADLE, im-
proved contractile function to a similar extent as when
preconditioned with hypoxia. The protection was removed
by the blocker of the mitochondrial ATP-sensitive potas-
sium channel (KATP), 5-hydroxydecanoate, indicating a
similarity to the effects of ischemic PC in other models (8).
Our semiquantitative analysis using RT-PCR confirmed
the presence of the messenger RNA transcript encoding the
d opioid receptors in the human atria and ventricles.
Therefore, it is reasonable to propose that d-opioid receptor
stimulation by DADLE can achieve a PC-mimetic effect in
human tissue, as previously shown by Gross and colleagues
(10,11) for similar receptor stimulation in the intact rat
heart and by ourselves and others (15,19) in the isolated rat
heart and the isolated rabbit heart (20).
Importance of opioid receptor subtypes. Since three opi-
oid receptor genes have been described, we designed specific
primer pairs based on published sequences of genes. The
RT-PCR products from these primer pairs were the pre-
dicted size when analyzed by DNA gel electrophoresis. We
readily found transcripts encoding the d and m receptors
Figure 2. (A) Representative RT-PCR reactions at 35 cycles (Cyc) and 40 cycles, respectively. The control primers (GAPDH ([G]) have multiple bands
due to the different optimal annealing temperatures of the GAPDH primers compared with the opioid-receptor subtypes. The m and d receptor PCR
products are shown at the different cycle lengths. The k receptor nested PCR data are not shown. (B) This histogram demonstrates the relative intensities
(expressed in arbitrary units [AU]) of the PCR products of the opioid receptor subtypes in both human atrial and ventricular tissue. The AU for the m and
d receptor subtypes reflect the mean PCR product generated after 40 cycles of PCR, and the AU for the k receptor reflects the PCR products after the
second round of nested PCR. bp 5 base pair; MRNA 5 messenger RNA; PCR 5 polymerase chain reaction.
Table 1. Baseline Data
Group Developed Force (g)
Control 0.98 6 0.19
PC 0.87 6 0.06
DADLE 1.02 6 0.12
Naltrindole 1 PC 0.89 6 0.10
Naltrindole 0.90 6 0.15
5HD 0.99 6 0.09
5HD 1 PC 0.76 6 0.07
5HD 1 DADLE 0.85 6 0.10
Values are mean 6 SEM.
DADLE 5 delta opioid agonist; PC 5 preconditioning; 5HD 5
5-hydroxydecanoate.
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with a putatively lower copy number of the k receptor
transcript. This opioid receptor distribution pattern differs
from the rat heart where similar work has shown the
presence of d receptors, lesser evidence of k receptors but no
m receptors (13). Morphine has been shown to mimic the
effects of PC (10), and this cardioprotection is mediated by
the d opioid receptor (21). Recently Gross’ group has
suggested that it is the d subtype that mediates PC (22). As
such we used DADLE, the specific d opioid receptor
agonist, rather than morphine, and naltrindole, the d opioid
receptor antagonist, rather than naloxone, to target the d
opioid receptor. Nonetheless, as with most pharmacological
agents, it must be appreciated that specificity is always a
problem, and it needs to be appreciated that no agent is
completely specific under such experimental conditions.
For functional studies, human atrial trabeculae were used
because atrial tissue was easily accessible. Sampling such
tissue is routinely part of coronary artery bypass grafting,
and the right atrium has the advantage of being relatively
disease-free. Use of an in vitro model avoids confounding
factors such as presence of collateral flow, concomitant
physiological responses and additional and possibly unpre-
dictable effects of the drugs used on other organ systems.
The human atrial model of PC is reproducible between
investigators and appears to follow all the criteria used to
examine PC in animal models, that is, it responds to
adenosine stimulation, appears to be mediated by a PKC-
type mechanism and involves the KATP channel (18). The
end point of injury used is the recovery of developed force,
and not limitation of infarct size, and, therefore, we are
unable to say whether or not there is a decrease in myocyte
necrosis or whether the protection observed is as a conse-
quence of stunning. In addition it must be noted that we use
simulated ischemia, which differs from true ischemia in a
number of ways. This is a superfused preparation, which
enables removal of catabolites during the simulated isch-
emia, in addition, because we use a buffer preparation, not
blood, there is no exposure to blood borne carriers such as
complement, platelets or leukocytes.
As we are fully aware morphine is a drug that is used in
the management of pain that accompanies acute myocardial
infarction as well as in the perioperative period after
Figure 3. Developed force presented as a percentage of baseline developed force against time. This graph shows that the effect of PC with hypoxia may
be simulated by delta-opioid receptor agonism (DADLE) and that ischemic PC is blocked by the delta opioid receptor antagonist, naltrindole. p , 0.001
vs. control. C 5 control; DADLE 5 d opioid agonist; PC 5 preconditioning; naltrindole1PC 5 naltrindole plus preconditioning.
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coronary artery bypass surgery. It is an agent that mainly
stimulates the m (which is associated with the pain receptor)
in addition to having effects on the d and k receptors (23).
Our results, therefore, raise the possibility that such admin-
istration of morphine might, besides giving pain relief, also
protect the myocardium against further episodes of recur-
rent ischemia. But are doses of morphine given in clinical
practice likely to evoke a PC-like effect? In the isolated
rabbit heart, morphine concentrations of 0.3 uM can give
such protection, and in the rabbit heart in situ, 3mg/kg is
required (23). These doses are estimated by Miki et al. (24)
to be much higher than those clinically used. In the intact
rat, however, a total dose of 0.3 mg/kg could achieve a PC
effect (14). In humans, the standard doses are 2 to
10 mg/70 kg, that is, up to 0.14 mg/kg. The maximum
doses that have been used are 2 to 3 mg/kg, which are
regarded as remarkably large but well tolerated (25). Ac-
cording to a preliminary report (26), morphine in a dose of
only 15 mg/kg gave pharmacologic PC during repeat coro-
nary angioplasty. Of interest, 10 nM DADLE achieved
protection in both isolated rat heart experiments (15) and in
the present series on superfused human atria. Most recently
it has been shown that the opioid receptor antagonist
naloxone abolished the adaptation to ischemia observed in
humans after two sequential coronary balloon inflations
(27). Therefore, there is a real possibility that morphine, as
clinically used, may have a pharmacological PC effect,
especially at high doses.
The relevance of other receptor subtypes. The role of the
k receptor in opioid PC is still unclear although cardiopro-
tective effects of k receptor stimulation have been demon-
strated in rat ventricular myocytes subjected to metabolic
inhibition (28). In our own rat heart experiments (15) using
infarct size as the end point, we found that a high dose of
the delta-agonist DADLE did not protect the myocardium.
This lack of a cardioprotective effect was abolished by
simultaneous administration of the k-receptor blocker,
bremazocine. Since we know that k receptors are present in
rat heart (29), the suggestion is that k receptor stimulation
can oppose the protection achieved by d stimulation in the
Figure 4. Developed force presented as a percentage of baseline developed force against time. This graph shows that the effect of PC with both simulated
ischemia and DADLE. Both the effects of PC and DADLE are blocked by the mitochondrial KATP channel blocker 5HD. p , 0.001 vs. control. C 5
control; PC 5 preconditioning; DADLE 5 delta opioid agonist; 5HD 5 5-hydroxydecanoate; 5HD1PC 5 5 hydroxyceanoate plus preconditioning;
5HD1DADLE 5 5 hydroxydecanoate plus delta opioid agonist.
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rat heart (15). The fear that nonspecific k receptor stimu-
lation by morphine or DADLE could lessen the degree of
protection is real in the rat, but, importantly, our data show
that the k receptor is only present in very small amounts in
the human heart. If this is correct than any potential fear
that agents that exhibit a wide range of receptor subtype
activation, such as morphine, may not necessarily prove
detrimental or oppose the potential PC effect of such opioid
receptor activation.
Clinical relevance. Our data, taken together with those in
rats and rabbits, show that opioid receptor stimulation has
clinical potential and warrants further exploration in hu-
mans. There are a number of outstanding questions. First,
do the doses of morphine as clinically used achieve PC-like
protection? Moreover, could a pharmacologic dose of mor-
phine be combined with a lesser degree of ischemia to give
added PC as postulated in the case of protection mediated
by angiotensin-converting enzyme inhibition (30)? A pos-
sible future clinical application of our data lies in the
development of d-opioid agonists that could have fewer
central side-effects, yet with more direct protective effects on
the human myocardium. Specifically, it is the d1 receptor
subgroup that gives protection in the rat heart (14). Ago-
nists of this subgroup may have clinical application.
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